Gilead Gets Analyst Upgrade on 'Outstanding' HIV Treatment Data

Gilead Sciences (GILD) shares climbed successful intraday trading Monday aft Raymond James analysts upgraded nan supplier developer to “outperform” from “market perform.”

The patient issued a value target of $93, a astir 40% premium to Friday’s closing value of $66.69. Gilead shares were up 0.6% astir midday Monday but are down astir 15% this year. 

Raymond James Notes 'Outstanding Data' From Lenacapavir Phase 3 Trial

Raymond James pointed to “outstanding data” from a Phase 3 trial of Gilead’s injectable HIV curen lenacapavir, which showed a 100% effectiveness rate successful preventing HIV infection successful women. Gilead is expected to motorboat lenacapavir successful precocious 2025, assuming occurrence successful its adjacent study. 

The patient besides cited nan imaginable Food and Drug Administration (FDA) support of seladelpar for nan curen of superior biliary cholangitis (PBC), a chronic autoimmune illness affecting nan liver. Together, nan 2 treatments could make $3.7 cardinal successful mixed yearly income by 2030, according to Raymond James’ model.

Investopedia requires writers to usage superior sources to support their work. These see achromatic papers, authorities data, original reporting, and interviews pinch manufacture experts. We besides reference original investigation from different reputable publishers wherever appropriate. You tin study much astir nan standards we travel successful producing accurate, unbiased contented successful our editorial policy.